Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the target of a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 11,000 shares, an increase of 15.8% from the November 15th total of 9,500 shares. Currently, 0.2% of the shares of the stock are sold short. Based on an average trading volume of 25,400 shares, the days-to-cover ratio is currently 0.4 days.

Insider Activity at Aprea Therapeutics

In related news, Director Marc Duey sold 6,462 shares of the business’s stock in a transaction on Friday, October 18th. The stock was sold at an average price of $4.58, for a total value of $29,595.96. Following the sale, the director now owns 233,651 shares of the company’s stock, valued at $1,070,121.58. The trade was a 2.69 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bernd R. Seizinger acquired 10,000 shares of the company’s stock in a transaction on Friday, October 11th. The shares were bought at an average price of $2.68 per share, with a total value of $26,800.00. Following the completion of the purchase, the director now directly owns 44,730 shares of the company’s stock, valued at approximately $119,876.40. This represents a 28.79 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 42,290 shares of company stock valued at $165,096 over the last quarter. 12.80% of the stock is owned by company insiders.

Institutional Trading of Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Dimensional Fund Advisors LP acquired a new position in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned approximately 0.20% of Aprea Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Stock Performance

Aprea Therapeutics stock traded down $0.32 on Friday, reaching $3.20. The company’s stock had a trading volume of 25,108 shares, compared to its average volume of 20,368. The business’s fifty day moving average price is $3.41 and its 200 day moving average price is $3.60. The company has a market cap of $17.36 million, a price-to-earnings ratio of -1.14 and a beta of 0.88. Aprea Therapeutics has a twelve month low of $2.15 and a twelve month high of $8.85.

Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.11. The business had revenue of $0.35 million for the quarter, compared to the consensus estimate of $0.45 million. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%. As a group, equities analysts forecast that Aprea Therapeutics will post -2.55 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Aprea Therapeutics in a research note on Monday, November 18th.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.